Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 635

1.

Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10.

Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Hölscher T, Gut P, Guckenberger M, Hildebrandt G, Müller AC, Plasswilm L, Papachristofilou A, Stalder L, Biaggi-Rudolf C, Sumila M, Kranzbühler H, Najafi Y, Ost P, Azinwi NC, Reuter C, Bodis S, Kaouthar K, Wust P, Thalmann GN, Aebersold DM.

J Clin Oncol. 2015 Dec 10;33(35):4158-66. doi: 10.1200/JCO.2015.63.3529. Epub 2015 Nov 2.

PMID:
26527774
2.

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C, Logue J, Scrase C, Patterson H, Birtle A, Staffurth J, Malik Z, Panades M, Eswar C, Graham J, Russell M, Kirkbride P, O'Sullivan JM, Gao A, Cruickshank C, Griffin C, Dearnaley D, Hall E.

Lancet Oncol. 2015 Dec;16(16):1605-16. doi: 10.1016/S1470-2045(15)00280-6. Epub 2015 Oct 28.

3.

INITIAL SYMPTOMATIC PITUITARY METASTASIS IN A PATIENT WITH PROSTATE FOAMY GLAND CARCINOMA: TAILORING SAFE AND EFFECTIVE THERAPY.

Prpić M, Fröbe A, Zadravec D, Pažanin L, Jakšić B, Bolanča A, Kusić Z.

Acta Clin Croat. 2015 Jun;54(2):243-8.

PMID:
26415325
4.

Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy: A propensity score-matched analysis.

Song C, Kang HC, Kim JS, Eom KY, Kim IA, Chung JB, Hong SK, Byun SS, Lee SE.

Strahlenther Onkol. 2015 Oct;191(10):801-9. doi: 10.1007/s00066-015-0872-9. Epub 2015 Jul 10.

PMID:
26159555
5.

Regional hyperthermia and moderately dose-escalated salvage radiotherapy for recurrent prostate cancer. Protocol of a phase II trial.

Müller AC, Zips D, Heinrich V, Lamprecht U, Voigt O, Burock S, Budach V, Wust P, Ghadjar P.

Radiat Oncol. 2015 Jul 8;10:138. doi: 10.1186/s13014-015-0442-4.

6.

Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer.

Wang LS, Murphy CT, Ruth K, Zaorsky NG, Smaldone MC, Sobczak ML, Kutikov A, Viterbo R, Horwitz EM.

Cancer. 2015 Sep 1;121(17):3010-7. doi: 10.1002/cncr.29472. Epub 2015 May 29.

PMID:
26033633
7.

[Radiotherapy for local recurrences of prostate cancer after radical prostatectomy].

Grishina YA, Khmelevsky EV.

Vopr Onkol. 2015;61(1):7-13. Review. Russian.

PMID:
26016138
8.

The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation.

Ludwig MS, Kuban DA, Strom SS, Du XL, Lopez DS, Yamal JM.

BMC Cancer. 2015 Mar 27;15:190. doi: 10.1186/s12885-015-1180-6.

9.

Guidance of treatment decisions in risk-adapted primary radiotherapy for prostate cancer using multiparametric magnetic resonance imaging: a single center experience.

Panje C, Panje T, Putora PM, Kim SK, Haile S, Aebersold DM, Plasswilm L.

Radiat Oncol. 2015 Feb 22;10:47. doi: 10.1186/s13014-015-0338-3.

10.

Stereotactic body radiation therapy salvage reirradiation of radiorecurrent prostatic carcinoma relapsed in the prostatic bed.

Arcangeli S, Gambardella P, Agolli L, Monaco A, Dognini J, Regine G, Donato V.

Tumori. 2015 Apr 28;101(2):e57-9. doi: 10.5301/tj.5000251.

PMID:
25721678
11.

Therapeutic outcomes of neoadjuvant and concurrent androgen-deprivation therapy and intensity-modulated radiation therapy with gold marker implantation for intermediate-risk and high-risk prostate cancer.

Kobayashi M, Hatano K, Fukasawa S, Komaru A, Namekawa T, Imagumbai T, Araki H, Hara R, Ichikawa T, Ueda T.

Int J Urol. 2015 May;22(5):477-82. doi: 10.1111/iju.12707. Epub 2015 Feb 11.

PMID:
25684541
12.

The case for prostate brachytherapy in the Affordable Care Act era.

Durkee BY, Buyyounouski MK.

Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):465-7. doi: 10.1016/j.ijrobp.2014.10.014. Epub 2015 Jan 30. No abstract available.

PMID:
25680591
13.

The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy.

Thurner EM, Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, Kapp KS, Langsenlehner T.

Eur J Cancer. 2015 Mar;51(5):610-9. doi: 10.1016/j.ejca.2015.01.002. Epub 2015 Jan 21.

PMID:
25618827
14.

[Modern therapy of prostate cancer].

Kretschmer A, Stief C, Gratzke C.

MMW Fortschr Med. 2014 Dec 15;156(21-22):71-3. Review. German. No abstract available.

PMID:
25608415
15.

The role of 18F-flourocholine PET/CT in biochemically relapsed prostate cancer: a case of osteolytic prostate metastasis.

Tabrizipour AI, Dunne M.

Clin Nucl Med. 2015 May;40(5):e285-6. doi: 10.1097/RLU.0000000000000681.

PMID:
25608148
16.

Five-year follow-up using a prostate stent as fiducial in image-guided radiotherapy of prostate cancer.

Carl J, Sander L.

Acta Oncol. 2015 Jun;54(6):862-7. doi: 10.3109/0284186X.2014.987355. Epub 2014 Dec 24.

PMID:
25539443
17.

Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy.

Raleigh DR, Hsu IC, Braunstein S, Chang AJ, Simko JP, Roach M 3rd.

Brachytherapy. 2015 Mar-Apr;14(2):185-8. doi: 10.1016/j.brachy.2014.11.008. Epub 2014 Dec 19.

PMID:
25533416
18.

Natural History after Biochemical Failure Following Dose-escalated External Beam Radiation: An Opportunity to Improve Outcomes?

Roach M 3rd.

Eur Urol. 2015 Jun;67(6):1017-8. doi: 10.1016/j.eururo.2014.10.015. Epub 2014 Oct 28. No abstract available.

PMID:
25457015
19.

Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience.

Servoll E, Sæter T, Vlatkovic L, Nesland JM, Waaler G, Axcrona K.

Scand J Urol. 2015 Jun;49(3):218-23. doi: 10.3109/21681805.2014.982168. Epub 2014 Nov 27.

PMID:
25428750
20.

Low incidence of new biochemical hypogonadism after intensity modulated radiation therapy for prostate cancer.

Markovina S, Weschenfelder DC, Gay H, McCandless A, Carey B, DeWees T, Knutson N, Michalski J.

Pract Radiat Oncol. 2014 Nov-Dec;4(6):430-6. doi: 10.1016/j.prro.2014.02.004. Epub 2014 May 17.

PMID:
25407866
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk